**KENNETH A. ICZKOWSKI, M.D.**

Home: 950 Wild Rose Ct. Work: Professor, Dept. of Pathology, Laboratory Bldg. L67

Brookfield, WI 53045 9200 W. Wisconsin Ave.

Home phone: 262-794-3856 Milwaukee, WI 53226

e-mail: kaiczkowski@mcw.edu Work phone: 414-805-8451 FAX: 414-805-8444

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

*Personal*

Married 1999. Two children, born 2001 and 2004.

*Education and Training*

FELLOW IN UROLOGIC PATHOLOGY, January, 1997—May, 1998

Mayo Clinic, Rochester, Minnesota

David G. Bostwick, M.D., Genitourinary Pathologist, Director

FELLOW IN ANATOMIC PATHOLOGY, July, 1995—December, 1996

University of Kansas Medical Center, Kansas City, Kansas

Cooley G. Pantazis, M.D., Chief, Surgical Pathology Division

*Responsibilities: surgical pathology, frozen sections, cytology cases, supervising residents, tumor board and case presentations, and independent research.*

RESIDENT IN PATHOLOGY, 1992—1995

Dartmouth‑Hitchcock Medical Center

Lebanon, New Hampshire

William F. Hickey, M.D., Former chairman

DOCTOR OF MEDICINE, 1992

St. Louis University School of Medicine, St. Louis, Missouri

POST‑SOPHOMORE FELLOWSHIP, PATHOLOGY, 1989—90

St. Louis University Medical Center, St. Louis, Missouri

Carole Vogler, M.D., Director, Residency Training Program

BACHELOR OF ARTS (BIOLOGY), 1986

Columbia College of Columbia University

New York, New York GPA 3.68

*Professional Experience*

PROFESSOR, DEPARTMENTS OF PATHOLOGY AND UROLOGY, MEDICAL COLLEGE OF WISCONSIN, July 1, 2017- Milwaukee, WI

ASSOCIATE PROFESSOR, DEPARTMENTS OF PATHOLOGY AND UROLOGY, MEDICAL COLLEGE OF WISCONSIN, August 1, 2013- June 30, 2017 Milwaukee, WI

DIRECTOR, UROLOGIC PATHOLOGY, GoPath PATHOLOGY ASSOCIATES, S.C.

 October 2012―July 2013, Buffalo Grove, IL

DIRECTOR OF LABORATORY, UROLOGY SPECIALISTS OF AMERICA, L.L.C.

 June 2011—August 2012, Columbus, OH

ASSISTANT & ASSOCIATE PROFESSOR, PATHOLOGY, UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

 2007—2011, Aurora, Colorado

ASSISTANT PROFESSOR, PATHOLOGY, UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE, and

STAFF PATHOLOGIST, VETERANS ADMINISTRATION MEDICAL CENTER,

 August 21, 2000—2007, Gainesville, Florida

 *Rotation Director, VA Surgical Pathology Resident Rotation*

STAFF PATHOLOGIST, July 1998—July 2000, Reading Hospital and Medical Center, Reading, PA

*Certification*

Diplomate, American Board of Pathology (Anatomic Pathology), 11/8/95.

Diplomate, National Board of Medical Examiners, 1993.

*Licenses* Illinois 036.135591 (exp. 07/31/20)

 Wisconsin 60981-20 (exp. 10/31/17)

**Patents:**

U.S. Patent No. 7,745,121. “Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer. Inventors: Katherine Siegler, Kenneth Iczkowski, Richard Bucala, Pedro L. Vera. Issued June 29, 2010.

U.S. Patent No. 11/579,785. “CD44 Variants 8-10 as Serum and Tissue Markers for Prostate Cancer.” Held jointly with A. Levi Omara-Opyene. Issued Jul 17, 2008.

Application in progress for “Serum NAG-1 Protein as a Marker for Prostate Cancer.” Provisional patent filed, UF#-11250, University of Florida

**Funding and Grant Support:**

**Current Collaborations: Co-Investigator**

“Project 2: Genetic & Physiological Basis of Salt-Sensitive Hypertension”
1R01HL121233-01A1. Collaborator with 5% Salary support. NIH. P.I.: Mingyu Liang, Ph.D. Effective 07/01/2016-05/31/2018.

 “Bayesian Ensemble Prediction for Identifying and Classifying Heterogeneity of Cell Types in Prostate Cancer” (PI: Peter LaViolette), Independent Research Seed Grant in Prostate Cancer Research – FP6760. Medical College of Wisconsin Cancer Center. Total cost $100,000, no salary support. May 1, 2016-April 30, 2018.

**Prior Funding as P.I.**

 “Alternate Splicing of CD44 Messenger RNA in Prostate Cancer Growth” (PI: Iczkowski), Department of Defense Prostate Cancer Research Program, Grant Number PC060671. Direct cost: $173,116; Indirect cost: $93,483; Total cost: $266,599. April 1, 2007-October 31, 2009.

“Aberrant CD44 Messenger RNA in Prostate Carcinoma” (PI: Iczkowski), Research Scholar Grant, American Cancer Society, Grant Number RSG-02-157-01-CCE. Total cost $183,000. July 1, 2002-June 30, 2006.

“Aberrant CD44 Messenger RNA in Prostate Carcinoma” (PI: Iczkowski), Merit Review Entry Program, Veterans Administration, Grant Number 821-02. Total cost reduced to $26,667. October 1, 2002-2005.

“Trials of New Germ Cell Immunohistochemical Stains in Extragonadal and Metastatic Germ Cell Tumors” (PI: Iczkowski), Clinical Research Committee, University of Florida College of Medicine. Total cost $2,481.70. October 1, 2005-September 30, 2006.

“In Situ Hybridization for CD44 Variant Isoform mRNA in Prostate Carcinoma” (PI: Iczkowski), Clinical Research Committee, University of Florida College of Medicine. Total costs $4,143. April 1, 2001-March 30, 2002.

“NSAID-Activated Gene-1 (NAG-1) as a Marker for Prostate Cancer” (PI: Iczkowski), Clinical Research Committee, University of Florida College of Medicine. Total costs $4,581. July 1, 2002-June 30, 2003.

“Cell adhesion protein pinin (DSR/memA) expression in prostate cancer and other human tumors” (PI: Iczkowski), Clinical Research Committee, University of Florida College of Medicine. Total costs $1,983. October 1, 2004-September 30, 2005.

**Prior Funding as Co-Investigator**

“Histological Validation of MRI of the Prostate” (PI: Peter LaViolette), Independent Research Seed Grant in Prostate Cancer Research – FP6760. Medical College of Wisconsin Cancer Center. Total costs $100,000. May 1, 2014-April 30, 2016.

“Mycoplasmal Effects of Human Tumor Invasion” (PI: Rosser), Research Scholar Grant, American Cancer Society. Co-investigator (10% Effort). $2605 in 2007-8; $2705 in 2008-9; $2809 in 2009-10.

“MIF in the Human Prostate: Cancer Biomarker Validation and Cell Biology” (PI: Katherine Siegler, Ph.D.), Veterans Affairs Merit Review, Co-Investigator with 5% effort and $6000/year, April 1, 2007-March 31, 2010.

“Cyclin dependent kinase inhibitors in tumor growth in vivo” (PI: Ostrov), Clinical Research Committee, University of Florida College of Medicine. Total costs $3,000, October 1, 2005-September 30, 2006.

**Past collaborations in funded grants**

**Consultant** with Dr. Steve Goodison (PI), Department of Surgery, University of Florida. “Isolation of metastasis-inhibiting monoclonal antibodies in breast cancer.” Susan Komen Foundation Award, 2006-8.

**Paid Co-Investigator** with Dr. Pedro Vera, NIH (NIDDK) R21 grant entitled "Role of MIF in neurogenic inflammation of the Prostate and the Bladder” October 1, 2006-2009. 5% effort.

**Paid Co-Investigator** with Dr. Katherine Siegler, VA Merit Review grant entitled “MIF in the human prostate: cancer biomarker validation and cell biology” April 1, 2007-2010. 5% effort, $6000/year.

**Submitted, not funded**

1 R21 CA143888-01. “Evaluation of Efficacy of Polymanan Extract (Long-Chain Glucomannans) on Prostate Cancer Cells” (PI: Iczkowski, AN3312383). Submitted, July 2010.

**Teaching of Medical and Dental Students and Residents:**

*2007-2017* Gave lecture series and conducted small group sessions in pathology for 2nd year students.

*2003-2005* Coordinated the clinicopathologic Case Presentations by second-year medical students.

*2003-2005* Coordinated and taught student rotation in VA Surgical Pathology for second-year medical students.

*2003-2005* Lectured on Prostate Cancer to second-year medical students.

*2003-2005* Lectured on Prostate Cancer and Breast Cancer to dental students.

 *Pathology Residents:*

*2000-present* Core Lecture and Conference Series. Responsibilities: 3 Lectures

 November 21, 2002 Lecture: Prostate cancer

 October 9, 2003 and September 14, 2004 Lecture: Testis and testicular adnexa

**Abstracts**

Mostafa, M., Banerjee, A., Rowan, D., Abdelkader, A., **Iczkowski, K.A.** Variation in Nuclear Size and PD-L2 Positivity Correlate with Aggressive Chromophobe Renal Cell Carcinoma*,* abstract confirmation #369, to the United States & Canadian Academy of Pathology’s 107th Annual Meeting, March 17th – 23th, 2018 in Vancouver, BC. Modern Pathology 2018;31: 5xxA.

Kravtsov, O., Lucia, M.S., Rybicki, B., Lambert, J.R., Torkko, K.C., **Iczkowski, K.A.** Racial Disparity in Expression of NF-κB and GDF15 in Prostate Cancer and Accompanying Benign Prostatic Epithelium: Dependence on Stage and Grade*,* abstract confirmation #370, to the United States & Canadian Academy of Pathology’s 107th Annual Meeting, March 17th – 23th, 2018 in Vancouver, BC. Modern Pathology 2018;31: 5xxA.

Magers, M., **Iczkowski, K.A.**, Montironi, R., Grignon, D., Zhang, S., Williamson, S.R., Yang, X., Wang, M., Osunkoya, A.O., Hes, O., Eble, J., Cheng, L. Analysis of MYB-NFIB Gene Fusion in Prostatic Basal Cell Carcinoma/Adenoid Cystic Carcinoma: Clinicopathologic Correlates and Comparison with Basal Cell Hyperplasia/Adenoma, abstract confirmation #628, to the United States & Canadian Academy of Pathology’s 107th Annual Meeting, March 17th – 23th, 2018 in Vancouver, BC. *Modern Pathology* 2018;31: 5xxA.

Sean D McGarry, Sarah L Hurrell, **Iczkowski, K.A.**, et al. Predictive Cytological Topography (PiCT): a Radio-Pathomics Approach to Mapping Prostate Cancer. Presented at the International Society for Magnetic Resonance in Medicine--European Society for Magnetic Resonance in Medicine and Biology, 27th Annual Meeting, June 15-18, 2018 in Paris.

Sean D McGarry , Matthew D Budde , Sarah L Hurrell , Kenneth A Iczkowski , Michael Griffin , Petar D Duvnjak , Kenneth Jacobsohn , William Hall , Mark Hohenwalter , and Peter LaViolette. The Medical College of Wisconsin 39 (MCW39): A Magnetic Resonance Image Template of the Prostate to Facilitate Group Analysis Presented at the International Society for Magnetic Resonance in Medicine--European Society for Magnetic Resonance in Medicine and Biology, 27th Annual Meeting, June 15-18, 2018 in Paris.

Singh, C.K., Malas, K.M., Tydrick, C., **Iczkowski, K.A.**, Ahmad, N. Role of zinc transporters in prostate cancer and a potential association with racial disparity [abstract]. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR); 2017 Apr 1-5; Washington, DC; Abstract nr: LB-228.

Kaczmarowski, A., **Iczkowski, K.A.**, Hurrell, S.L., McGarry, S.D., Jacobsohn, K., Hall, W.A., Hohenwalter, M., See, W., and Laviolette, P.S. Predictive Cytological Topography (PiCT): a Radiopathomics Approach to Mapping Prostate Cancer Cellularity. The ISMRM 25th Annual Meeting & Exhibition in Honolulu, Hawaii, 22-27 April 2017.

**Iczkowski, K.A.**, Kaczmarowski, A.L., Jacobsohn, K., Hurrell, S.L., McGarry, S., Hohenwalter, M., Banerjee, A., LaViolette, P.S. Predictive Cytologic Topography Improves Detection of High-Grade Prostate Cancer on MRI”, abstract confirmation #6855, to the United States & Canadian Academy of Pathology’s 106th Annual Meeting, March 4th – 10th, 2017 in San Antonio, TX. *Modern Pathology* 2017;30: 530A.

Kravtsov, O., Solanki, M., Lambert, J.R., Torkko, K.C., Lucia, M.S., and **Iczkowski, K.A.** “Racial Disparity in Expression of GDF-15 and NF-kB in Prostate Cancer and Benign Prostate”, abstract confirmation #1251, to the United States & Canadian Academy of Pathology’s 106th Annual Meeting, March 4th – 10th, 2017 in San Antonio, TX. *Modern Pathology* 2017;30: 236A.

Ronen, S., Lapadat, R., Giorgadze, T., Peterson, J.F, **Iczkowski, K.A.** and Hunt, B. Comparing UroVysion and Urine Cytology as a Quality Assurance Metric and to Evaluate the Relevance of the Paris System for Reporting Urinary Cytology in Our Institution”, abstract confirmation #10465, to the United States & Canadian Academy of Pathology’s 106th Annual Meeting, March 4th – 10th, 2017 in San Antonio, TX. *Modern Pathology* 2017;30: 517A.

Abbott, D.W., Ronen, S., Abdelkader, A., Banerjee, A., Xu, Y., Kravtsov, O., and **Iczkowski, K.A.** PTEN and p27 Loss Differ Among Morphologic Patterns of Prostate Cancer”, abstract confirmation #1096, to the United States & Canadian Academy of Pathology’s 106th Annual Meeting, March 4th – 10th, 2017 in San Antonio, TX. *Modern Pathology* 2017;30: 210A.

Ronen, S., Hartley, C., **Iczkowski, K**. Programmed Death-Ligand 1 Expression Correlates with No Downstaging After Platinum Therapy in Muscle-Invasive Bladder Cancer”, abstract confirmation #1032, to the United States & Canadian Academy of Pathology’s 106th Annual Meeting, March 4th – 10th, 2017 in San Antonio, TX. *Modern Pathology* 2017;30: 252A.

Singh, C.K., Shabbir, M., Nihal, M., **Iczkowski, K.A.**, Ahmad, N. Polo-like kinase 4: A potential new target for the management of prostate cancer [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR); 2016 Apr 16-20; New Orleans, LA; Abstract nr: LB-228.

**Iczkowski, K.A.**, Lambert, J.R., Torkko, K.C., Eastwood, D. C., Wilson, R.S., Shah, G.V., Lucia, M.S. Racial disparity in prostatic expression of pro-inflammatory and paracrine factors. *Modern Pathology* 2016;29: 240A.

Whittington, E., Harding-Jackson, N., Pavan, N., Rai, S., **Iczkowski, K.A.**, Kryvenko, O.N., Jorda, M. Invasion of rete testis, hilar fat, and epididymis by testicular malignant germ cell tumors does not justify upstaging to pT2 [Platform presentation]. *Modern Pathology* 2016;29: 270A.

Kilari, D., **Iczkowski, K.A.**, Pandya, C., Robin, A., Messing, E.M., Guancial, E., Kim, E.S. Copper transporter CTR1 expression predicts platinum response in muscle-invasive bladder cancer. *Modern Pathology* 2016;29: 242A

Harding-Jackson, N., Whittington, E., Eastwood, D.C., Tjionas, G.A., Kryvenko, O.N., Upadyhyay, S., Jorda, M., **Iczkowski, K.A.** Prostate cancer grade group 4: Gleason 3+5=8 and 5+3=8 outcomes versus 4+4=8. *Modern Pathology* 2016;29: 237A.

LaViolette, P. S., Kaczmarowski, A., **Iczkowski, K.A.**, Jacobsohn, K., Knechtges, P.M., Hohenwalter, M., See, W. MRI-derived histologically trained maps of epithelium density predict prostate cancer presence. *Modern Pathology* 2016;29: 396A.

Stoll, K., Popp, L., LaViolette, P.S., **Iczkowski, K.**, Mackinnon, A.C. The introduction of whole mount prostate specimens into a routine histology laboratory aided by 3D printing. National Society of Histotechnology 2015 Symposium.  *J. Histotechnology*.

Kilari,D., **Iczkowski, K.A.**, Pandya, C., Robin, A.J., Messing, E.M., Guancial E., Kim, E.S.Association between copper transporter CTR1 expression and pathologic response in cisplatin (Pt)-treated muscle invasive bladder cancer (MIBC) patients. European Cancer Congress, Poster session, Vienna, Austria 26 Sept. 2015. Also published for U.S. meeting, May 29, 2015.

Li, H., Hes, O., MacLennan, G., **Iczkowski, K.A.** Immunohistochemical distinction of primary adrenal nodules, including oncocytic tumor, from metastases of renal cell carcinoma to the adrenal. *Modern Pathology* 2015;28: 239A.

**Iczkowski, K.A.,** Harding-Jackson, N. Intraductal carcinoma of the prostate: Interobserver variability Survey of 39 urologic pathologists. *Modern Pathology* 2015;28: 227A.

**Iczkowski, K.A.,** Li, H., Eastwood, D., Hes, O. Immunohistochemical distinction between metastatic renal cell carcinoma to the adrenal and primary adrenal lesions. Presented at CAP ’14, #23, Sep. 8, 2014, Chicago.

**Iczkowski, K.A.,** Kilari, D., Pandya, C. Association between copper transporter receptor 1 (CTR1) expression and pathologic outcomes in cisplatin-treated bladder cancer patients. Presented at CAP ’14, #21, Sep. 8, 2014, Chicago.

**Iczkowski, K.A.,** Guo, Z., Lu, Z. MMP-26 may detect prostate cancer risk regardless of needle biopsy pathology. Presented at CAP ’14, #15, Sep. 8, 2014, Chicago.

**Iczkowski, K.A.** Not all Gleason grade 4 prostate cancer is alike: Differential CD44 variant expression between cribriform pattern and fused small acini. Presented at CAP ’14, #45, Sep. 8, 2014, Chicago.

**Iczkowski, K.A.**, Torkko, K.C., Wilson, R.S., Lucia, M.S., Bostwick, D.G. Weak association of prostatic atrophy with high-grade PIN and low-grade cancer: topographic digital study of 48 whole-mounted prostatectomy specimens. *Modern Pathology* 2013;26: 219A.

**Iczkowski, K.A.**, Torkko, K.C., Kotnis, G.R., Wilson, R.S., Huang, W., Wheeler, T.M., Abeyta, A.M., La Rosa, F.G., Cook, S., Werahera, P.N., Lucia, M.S. Digital quantification of the cribriform and 7 other patterns of prostate cancer and their association with PSA failure. *Modern Pathology* 2011;24: 200A.

Zhang, C., MacLennan, G.T., Montironi, R., Lopez-Beltran, A., Li, Y., Pan, P.-H., **Iczkowski, K.A.**, Cheng, L. Atypical adenomatous hyperplasia (AAH) that is associated with prostatic adenocarcinoma has higher expression of α-methytlacyl coenzyme A racemase (AMACR) than AAH not associated with cancer. *Modern Pathology* 2011;24: 232A.

Vera, P., **Iczkowski, K.**, Meyer-Siegler, K. Cyclophosphamide upregulates and induces urothelial cell surface expression of thrombomodulin and endothelial protein C receptor: a possible role for activated protein C in cystitis. Poster presentation. *The Journal of Urology* 2010;183: Supplement, e238-9.

Khamis, Z.I., **Iczkowski**, **K.A.,** Sang, Q.X. Protein biomarkers of human prostate cancer stromal cells. American Association for Cancer Research 101st Annual Meeting, April 17-21, 2010, Washington DC. Permanent abstract number: 551; Tumor Biology 9. Poster presentation date: April 18, 2010. *Cancer Research*, 2010.

Sangoi, A.R., Beck, A.H., Amin,M.B., Cheng, L., Epstein, J.I., Hansel, D.E., **Iczkowski, K.A.**, Ro, J.Y. , Lopez-Beltran, A., Oliva,E., Paner, G.P., Reuter, V.E., Shah, R.B., Shen, S.S., Tamboli, P. McKenney, J.K. Interobserver reproducibility (IR) in the diagnosis of invasive micropapillary carcinoma (MPC) of the genitourinary tract among expert urologic pathologists. *Modern Pathology* 2010;23: 216A.

**Iczkowski, K.A.**, Torkko, K.C., Huang, W., La Rosa, F.G., Cook, S. The cribriform pattern in prostate cancer predicts PSA failure. *Modern Pathology* 2010;23: 197A.

Vera, P., **Iczkowski, K.A.**, Howard, D.J., Jiang, L., and Meyer-Siegler, K.L. Antagonism of macrophage migration inhibitory factor prevents cyclophosphamide cystitis in mice. Podium presentation. *The Journal of Urology* 2009;181: Supplement, e236-7.

Sakamoto, N., Namiki, K., Goodison, S., Urbanek, C., Reyes, L., Porvanik, S., Cao, W., Sakai, Y., **Iczkowski, K.A.**, Boehlein, S.K., Rosser, C.J. Chronic mycoplasmal exposure leads to malignant transformation of benign human cells. *The Journal of Urology* 2009;181: Supplement, e399.

Shah, G., Srivastava, A., **Iczkowski, K.A.** Neuroendocrine marker: a novel, reliable early stage marker for prostate cancer. AACR Meeting Abstracts, 2009:Apr 2009, 4826.

Butler, S.L., Kim, S., MacLennan, G.T., Shanks, J.H., Hossain, D., Schall, A., McKenney, J.K., Meiers, I., Schlesinger, C., **Iczkowski, K.A.** New immunostains for extragonadal and metastatic germ cell tumors. *Modern Pathology* 2007;20:139A.

Meyer-Siegler, K.L., Vera, P.L., **Iczkowski, K.A.**, Bifulco, C., Lee, A., Gregersen, P.K., Leng, L., Bucala, R. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with susceptibility and severity of prostate cancer. Society for Neuroscience Annual Meeting, 2007, Abstract No. 1622.

**Iczkowski, K.A**., Coco, D., Iturraspe, J.A., Pantazis, C.G. Telomerase overexpression by flow cytometry in myelodysplastic syndrome. *Modern Pathology* 2007;20:245A.

Nakamura, K., Goodison, S., **Iczkowski, K.**, Anai, S., Boehlein, S. Rosser, C. Exogenous mycoplasmal p37 protein alters gene expression, growth, and morphology of prostate cancer cells. AACR Meeting Abstracts, Apr 2007; 2007: 3698.

Vera, P.L., **Iczkowski, K.A.**, Moldwin, R.M., Kushner, L., Meyer-Siegler, K.L. Macrophage migration inhibitory factor and its receptor CD74 are upregulated in the urothelium of interstitial cystitis patients. Abstract 287, American Urological Association meeting, May 20-25, 2006, Atlanta.

Anai, S., Nakamura, K., Goodison, S., Shiverick, K., **Iczkowski, K.**, Tanaka, M., Rosser, C.J. A combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. AACR Meeting Abstracts 2006; Apr 2006: 1246.

Anai, S., Goodison, S., **Iczkowski, K.A.**, Shiverick, K., Brown, B., Rosser, C.J. Synergistic radiosensitization by antisense Bcl-2 oligodeoxynucleotide (ODN) in the PC-3 prostate tumor model overexpressing Bcl-2. *Proceedings, Amer. Assn. for Cancer Research* 2005;45.

Vera, P.L., **Iczkowski, K.A.**, Meyer-Siegler, K.L. Increased urinary levels of macrophage migration inhibitory factor in patients with urinary tract infections: identification of novel MIF-protein complexes in human urine. *The Journal of Urology* 2005;173 (Supplement 4): 21.

Meyer-Siegler, K.L., **Iczkowski, K.A.**, Leng, L., Bucala, R., Vera, P.L. Further evidence for an association between macrophage migration inhibitory factor and prostate cancer. *The Journal of Urology* 2005;173 (Supplement 4): 382.

Kim, W. Boehlein, S., **Iczkowski, K.**, Rosser, C.J., Anai, S**.** Environmental stressors to prostatic cancer cells in vitro cause an up-regulation of COX-2 expression**.** *AACR Meeting Abstracts*, 2005;Apr 2005: 406-407.

De Marzo, A.M., Platz, E.A., Epstein, J.I., Billis, A., Chan, T.Y., Cheng, L., Datta, M., Ertoy-Baydar, D., Farre, X., Fine, S., **Iczkowski, K.A.**, et al. Interobserver reproducibility of a proposed classification of focal prostate atrophy lesions. *Modern Pathology* 2005;18: 135A.

**Iczkowski, K.A.**, Qiu, J., Qian, J., Somerville, M.C., Rittmaster, R.S., Andriole, G.L., Bostwick, D.G. The dual 5α-reductase inhibitor dutasteride incudes atrophic changes and decreases relative cancer volume in the human prostate. *Modern Pathology* 2005;18: 146A.

**Iczkowski, K.A.**, MacLennan, G.T., Bostwick, D.G., Ferguson, K.L., Montironi, R. Adenoid cystic/ basal cell carcinoma of the prostate expresses Her-2/neu. *Modern Pathology* 2005;18: 147A,.

**Iczkowski, K.A.**, Omara-Opyene A.L. Altered expression of CD44 variants 7-10 facilitates prostate cancer invasion. *Proceedings, Amer. Assn. for Cancer Research* 2004;44: 1161.

Huang, W., **Iczkowski, K.A**., Mazzucchelli, R., Montironi, R. Androgen ablation therapy for prostate cancer suppresses telomerase hTERT immunoreactivity. *Modern Pathology* 2004;17: 158A.

**Iczkowski, K.A**., Jiang, Z., Tretiakova, M., Yang, X.J. Prostatic needle biopsies with suspicious (ASAP) diagnosis: 80% resolved using P540S/AMACR and keratin 34βE12 immunostaining. *Modern Pathology* 2003;16: 154A.

**Iczkowski, K.A.**, Grier, D.D., Bostwick, D.G., Hossain, D., Banerjee, S.S. Adenoid cystic/ basal cell carcinoma of the prostate: clinical significance in 18 cases. *Modern Pathology* 2003;16: 152A.

**Iczkowski, K.A**., Katz, G., Cascione, C.J., Grier, D.D. Postoperative bladder washing cytology after transurethral resection predicts recurrence of urothelial carcinoma. *Modern Pathology* 2003;16: 154A.

Katz, G., **Iczkowski, K.A**., Cascione, C., Rodriguez, R.E. Bladder washing cytology immediately after transurethral resection predicts recurrence of urothelial carcinoma. *The Journal of Urology* 2003;169 (Supplement 4): 258.

**Iczkowski, K.A.**, Chen, M., Yang, X. Atypical small acinar proliferation suspicious for carcinoma in prostatic needle biopsy does not predict unique pathologic findings if cancer is subsequently diagnosed. *Modern Pathology* 2002;15: 165A.

**Iczkowski, K.A**., Jones, G.L., Casella, G., Qian, J., Bostwick, D.G. Variation in tissue sampled by sextant biopsy influences prostate cancer detection rate. *Modern Pathology* 2002;15: 165A.

Pantazis, C.G., **Iczkowski, K.A.**, McGregor D., Tawfik, O.W. Telomerase subunit hTERT immunoreactivity in prostate cancer. *Modern Pathology* 2002;15: 176A.

**Iczkowski, K.A.** Characteristics of men initially diagnosed by needle biopsy with atypical small acinar proliferation (ASAP) suspicious for carcinoma. *American Journal of Clinical Pathology* web site [www.ajcp.com](http://www.ajcp.com/), 2001.

**Iczkowski, K.A.**, Mishler, B.A., Qian, J., and Bostwick, D.G. Volume of prostate tissue sampled by sextant needle biopsy may influence detection rate for cancer. *Modern Pathology* 2001;14: 111A.

**Iczkowski, K.A.**, Gadaleanu, V., Shanks, J.H., Jones, E.C., Neumann, R., and Bostwick, D.G. Spindle cell neoplasms of urinary bladder: 36 cases with comparison of inflammatory pseudotumor (myofibroblastic tumor) and leiomyosarcoma. *American Journal of Clinical Pathology* 2000;114(4): 641-642.

**Iczkowski, K.A.**, and Bostwick, D.G. Sampling, submission, and report format for multiple prostate biopsies: A 1999 survey. *Modern Pathology* 2000;13: 102A.

Fan, F., Tawfik, O., **Iczkowski, K.**, Nothnick, W., and Thomas, P. Altered CD44 expression in endometriosis. *American Journal of Clinical Pathology* 1999;112(4): 544.

Rao, S., **Iczkowski, K.A.**, and Cheville, J.C. Cytokeratin expression in seminoma and embryonal carcinoma of the testis. *Modern Pathology* 1998;11:93A.

**Iczkowski, K.A.**, Pantazis, C., Shah, G.V., and Long, J. Salmon calcitonin-like peptide: A novel neuroendocrine tumor marker overexpressed by prostatic adenocarcinoma. *American Journal of Clinical Pathology* 1997;108(3): 339.

Pantazis, C.G., Liao, D. J., **Iczkowski, K.A.**, Li, S.A., and Li, J.J. Induction of prostatic carcinoma in the Noble rat: Analysis of early morphologic and cellular events. *Proceedings of the American Association for Cancer Research* 1997;38: 58.

**Iczkowski, K.A.**, Pantazis, C.G. and Collins, J. Loss of expression of isoforms of the cell adhesion molecule CD44 in prostatic adenocarcinoma and its metastases. *American Journal of Clinical Pathology* 1996;106 (3): 418.

**Book Chapters**

**Iczkowski, K.A.** Chapter 6, Prostate (Male Urinary System). In: Moran CA, Kalhor N, Weissferdt A. Oncologic Surgical Pathology. New York: Springer,In press, 2018.

**Iczkowski, K.A.** Updates of electronic content, Prostate (grading, ASAP, vanishing cancer, prostatitis, testis, general) in Pathologyoutlines.com, 2015-18.

**Iczkowski, K.A.** Postoperative spindle cell nodule pathology. Medscape, 2017. https://authoring.medscape.com/content/1611768

**Iczkowski, K.A.**, and Harding-Jackson, N. Chapter: Genitourinary System Tumors. In: Idowu MO, Dumur CI, Garrett CT. Molecular Oncology Testing for Solid Tumors: A Pragmatic Approach. New York: Springer, 2015.

**Iczkowski, K.A.** Topics: 3-7 Prostate: basal cell carcinoma; 3-13 Tumors of the seminal vesicles (primary adenocarcinoma, epithelial-stromal tumor, leiomyoma, leiomyosarcoma). In: H. Moch, T. Ulbright, P. Humphrey, V. Reuter, eds, WHO Classification of Tumors: Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon, France, IARC (International Agency for Research on Cancer) Press, 4th ed., 2015.

**Iczkowski, K.A.**, Ulbright, T. Chapter 35: Testis and Testicular Adnexa. In: L. Cheng and D.G. Bostwick, eds, Essentials of Anatomic Pathology: A Practical Guide with Emphasis on Differential Diagnosis and Diagnostic Criteria. New York: Springer, First edition, 2002; Second edition, 2006; Third edition, 2009; Fourth edition, 2015.

**Iczkowski, K.A.** e-Medicine electronic chapters on: Effect of Radiation on the Prostate; Inflammatory Myofibroblastic Tumor of Bladder; Leukemia and Lymphoma of the Prostate; Atypical Small Acinar Proliferations of the Prostate (with Dr Hong Fai Cheong and Dr Puay Hoon Tan); Sex Cord-Stromal Tumors of Testis. Dr. Tom Wheeler, genitourinary section editor, 2009.

**Iczkowski, K.A.**, Foster, C.S. Chapter 19: Cell Adhesion Markers. In: Ross, JS and Foster, CS, eds, Molecular Oncology of Prostate Cancer. Sudbury, MA, Jones and Bartlett, 2006.

**Iczkowski, K.A**, Bostwick, D.G. Chapter 2 (pages 5-10): Histopathology of Radiation Change in the Prostate and Evaluation of Residual Cancer. In: Dicker AP, Merrick GS, Gomella LG, Valicenti RK, Waterman F, eds, Basic and Advanced Prostate Brachytherapy. London, Martin Dunitz, 2005.

**Iczkowski, K.A.** Topics: Signs and symptoms of prostatic adenocarcinoma; Hemato-lymphoid tumors of the prostate; Tumors of seminal vesicles (primary adenocarcinoma, epithelial-stromal tumor, leiomyoma, leiomyosarcoma). In: J.N. Eble, G. Sauter, J. Epstein, I. Sesterhenn, eds, WHO Classification of Tumors: Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon, France, IARC (International Agency for Research on Cancer) Press, 3rd ed., 2004.

###### **Manuscripts (171+1) including: (130) Original Articles (not incl. 1 pending)**

Nir, G., Hor, S., Fazli, L., Skinnider, B., Tavassoli, P., Turbin, D., Villamil, C., Wang, G., Wilson, R.S., **Iczkowski, K.A.**, Lucia, M.S., Black, P., Karimi, D., Abolmaesumi, P., Goldenberg, S.L., Septimiu E. Salcudean, S.E. Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. Submitted: *Medical Image Analysis*.

McGarry, S.D., Hurrell, S.L.; **Iczkowski, K.A.**, Hall, W., Kaczmarowski, A.L., Banerjee, A., Keuter, T., Jacobsohn, K., Nevalainen, M., Hohenwalter, M.D., See, W.A. Predictive Cytological Topography (PiCT): a radiopathomics approach to mapping prostate cancer. *International Journal of Radiation Oncology\*Biology\*Physics* In press as of 2/18.

Egevad, L., Delahunt, B., Berney, D.M., Bostwick, D.G., Cheville, J., Comperat, E., Evans, A.J., Fine, S.W., Grignon, D.J., Humphrey, P.A., Hornblad, J, **Iczkowski, K.A.**, (28 authors). Utility of pathology Imagebase for standardization of prostate cancer grading. *Histopathology* 2018, In press.

Mostafa, M.E., Abdelkader, A., Kuroda, N., Pérez-Montiel, D., Banerjee, A., Hes, O., **Iczkowski, K.A.** Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. *Annals of Diagnostic Pathology* 2018;34:31-35.

Hurrell, S.L., McGarry, S.D., Kaczmarowski, A., **Iczkowski, K.A.**, Jacobsohn, K., Hohenwalter, M.D., Hall, W.A., See, W.A., Banerjee, A., Charles, D.K., Nevalainen, M.T., Mackinnon, A.C., LaViolette, P.S. Optimized *b*-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. *J Med Imaging (Bellingham)*, 2018;5:011004.

Maranto, C., Udhane, V., Hoang, D., Gu, L., Alexeev, V., Malas, K., Cardenas, K., Brody, J., Rodeck, U., Bergom, C., **Iczkowski, K.A.**, Jacobsohn, K., See, W., Schmitt, S., Nevalainen, M. Stat 5a/b blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair. In press, *Clinical Cancer Research* Feb 26. doi: 10.1158/1078-0432.CCR-17-2768. [Epub ahead of print]

**Iczkowski, K.A.**, Evans, D.E., Suster, S. Adrenal oncocytic pheochromocytoma with functionality in a neurofibromatosis patient: A case report. *Human Pathology Case Reports*, 2018, In press

Egevad, L., Cheville, J., Evans, A.J., Hörnblad, J., Kench, J.G., Kristiansen, G., Leite, K.R.M., Magi-Galluzzi, C., Pan, C.C., Samaratunga, H., Srigley, J.R., True, L., Zhou, M., Clements, M., Delahunt, B., **Iczkowski, K.A.**; **ISUP Pathology Imagebase Expert Panel**. Pathology Imagebase--a reference image database for standardization of pathology. *Histopathology* 2017;71:677-685.

Bayat, S., Azizi, S., Daoud, M., Nir, G., Imani, F., Gerardo, C., Yan, P., Tahmasebi, A., Vignon, F., **Iczkowski, K.**, Lucia, M.S., Goldenberg, L., Salcudean, T., Abolmaesumi, P., Mousavi, P. Investigation of physical phenomena underlying temporal enhanced ultrasound as a new diagnostic imaging technique: Theory and simulations. *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control* 2018;65:400-410.

Azizi, S., Bayat, S., Yan, P., Tahmasebi, A., Nir, G., Kwak, J.T., Xu, S., Wilson, S., **Iczkowski, K.A.**, Lucia, M.S., Goldenberg, L., Salcudean, S.E., Pinto, P., Wood, B., Abolmaesumi, P., Mousavi, P. Detection and grading of prostate cancer using temporal enhanced ultrasound: combining deep neural networks and tissue mimicking simulations. *International Journal of Computer-Assisted Radiology and Surgery* 2017;12:1293-1305.

Logunova, V., Sokumbi, O., **Iczkowski, K.A.** Metastatic sarcomatoid renal cell carcinoma manifesting as a subcutaneous soft tissue mass. *Journal of Cutaneous Pathology* 2017;44:874-877.

Baker, M.A., Davis, S.J., Liu, P., Pan, X., Williams, A.M., **Iczkowski, K.A.**, Gallagher, S.T., Bishop, K., Regner, K.R., Liu, Y., Liang, M. Tissue-specific microRNA expression patterns in four types of kidney disease. *Journal of the American Society of Nephrology* 2017;28:2985-2992.

Ronen, S., Abbott, D.W., Kravtsov, O., Abdelkader, A., Xu, Y., Banerjee, A., **Iczkowski, K.A.** PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. *Human Pathology* 2017;65:85-91.

Raychaudhuri, R., Riese, M.J., Bylow, K., Burfeind, J., Mackinnon, A.C., Tolat, P.P., **Iczkowski, K.A.**, Kilari, D. Immune check point inhibition in sarcomatoid renal cell carcinoma: A new treatment paradigm. *Clinical Genitourinary Cancer* 2017;15(5):e897-e901.

Singh, C.S., Malas, K.M., Tydrick, C., Siddiqui, I.A., **Iczkowski, K.A.**, Ahmad, N. Analysis of zinc-exporters expression in prostate cancer. *Scientific Reports*, 2016, Nov 11;6:36772.

Harding-Jackson, N., Kryvenko, O.N., Whittington, E.E., Eastwood, D.C., Tjionas, G.A., Jorda, M., **Iczkowski, K.A.** Outcome of Gleason 3+5=8 prostate cancer diagnosed on needle biopsy: Prognostic comparison with Gleason 4+4=8. *Journal of Urology*, 2016;196:1076-81.

Abbott, D., **Iczkowski, K.A.** Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy. *Case Reports in Clinical Pathology* 2016;3:60-63.

Siegele B., **Iczkowski, K.A.**, and LaRosa, F.G. Carcinosarcoma of the prostate in a patient with previous prostatic adenocarcinoma, status post brachytherapy: A case report and review of the literature. *International Journal of Clinical and Experimental Pathology* 2016;9(7):7724-7732.

Aljameeli, A., Thakkar, A., Thomas, S., Lakshmikanthan, V., **Iczkowski, K.A.**, Shah G.V. Calcitonin receptor-Zonula Occludens-1 interaction is critical for calcitonin-stimulated prostate cancer metastasis. *PLoS ONE* 2016; Mar 2;11(3):e0150090.

Kilari,D., **Iczkowski, K.A.**, Pandya, C., Robin, A.J., Messing E.M., Guancial E., Kim, E.S.Association between copper transporter CTR1 expression and pathologic response in cisplatin (Pt)-treated muscle invasive bladder cancer (MIBC) patients. *Anticancer Research* 2016;36:495-501.

Khamis, Z.I., **Iczkowski, K.A.**, Man, Y-G, Bou-Dargham, M.J., Sang, Q-X.A. Evidence for a proapoptotic role of matrix metalloproteinase-26 in human prostate cancer cells and tissues. *J Cancer* 2016; 7:80-87.

Li, H., Hes, O., MacLennan, G.T., Eastwood, D.C., **Iczkowski, K.A**. Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor. *Virchows Archiv* 2015;466:581-8.

Polanco, C., Pantazis, C.G., Prieto, R., **Iczkowski, K.A**. Papillary adenocarcinoma of the rete testis with adjacent hyperplasia: a case report. *Case Reports in Clinical Pathology* 2015;2:41-46.

Lambert,J.R., Whitson, R.J., **Iczkowski, K.A.**, La Rosa, F.G., Smith, M.L., Wilson, R.S., Smith, E.E., Torkko, K.C., Lucia, M.S.Reduced expression of GDF-15 associated with atrophic inflammatory lesions of the prostate. *Prostate* 2015;75:255-65.

**Iczkowski, K.A.** Paneth cell-like change in benign prostate can account for P504S (AMACR) reactivity. *International Journal of Clinical and Experimental Pathology* 2014;7(6):3454-5. eCollection 2014.

**Iczkowski, K.A.** et al. [39 authors]. Intraductal Carcinoma of the Prostate: Interobserver Reproducibility Survey of 39 Urologic Pathologists." *Annals of Diagnostic Pathology* 2014;18:333-42.

Villarreal-Calderon, R., Luévano-González, A., Aragón-Flores, M., Zhu, H., Yuan, Y., Xiang, Q., Yan, B., Stoll, KA., Cross, J.V., **Iczkowski, K.A.**, Mackinnon, A.C. Antral atrophy, intestinal metaplasia, and pre-neoplastic markers in Mexican children with *Helicobacter pylori*-positive and negative gastritis. *Annals of Diagnostic Pathology* 2014:18:129-35.

Dancik, G.M., Owens, C.R., **Iczkowski, K.A.**, Theodorescu, D. A Cell Of Origin gene signature indicates human bladder cancer has distinct cellular progenitors. *Stem Cells* 2014;32:974-82.

**Iczkowski, K.A.**, Torkko, K.C., Wilson, R.S., Lucia, M.S., Bostwick, D.G. Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. *Human Pathology* 2014;45:54-58.

Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Renal tumors: diagnostic and prognostic biomarkers. *Am J Surg Pathol.* 2013;37:1518-31.

Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR; members of the ISUP Renal Tumor Panel. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. *Am J Surg Pathol.* 2013;37:1505-17.

Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. [The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.](http://www.ncbi.nlm.nih.gov/pubmed/24025520) *Am J Surg Pathol.* 2013;37:1490-504.

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. [The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia.](http://www.ncbi.nlm.nih.gov/pubmed/24025519) *Am J Surg Pathol.* 2013;37:1469-89.

Raman, S.B., Nguyen, M.H., Cheng, S., Badrane, H., **Iczkowski, K.A.**,Wagener, M., Gaffen, S., Mitchell, A.P., Clancy, C.J. A competitive infection model of hematogenously disseminated candidiasis in mice redefines the role of Candida albicans IRS4 in pathogenesis. *Infection and Immunity* 2013;81:1430-8. Epub 2013 Feb 19.

Hohensee, S.E., La Rosa, F.G., Homer, P., Suby-Long, T., Wilson, S., Lucia, M.S., **Iczkowski, K.A.** Renal epithelioid angiomyolipoma with negative premelanosome marker immunoprofile: a case report and review of the literature. *Journal of Medical Case Reports* 2013, 7:118. www.jmedicalcasereports.com/content/7/1/118

**Iczkowski, K.A.**, Shanks, J.H., Burdge, A.H., Cheng, L. Renal cell carcinoma with clear cells, smooth muscle stroma, and negative for 3p deletion: a variant of renal angiomyoadenomatous tumor? *Histopathology* 2013;62:522-524.

Bhide, M., Bolshoun, P., Wilson, S., **Iczkowski, K.A.** Renal angiomyolipoma presenting as fever of unknown origin. *Open Journal of Urology* 2012;2 No. 3, 144-6. DOI: 10.4236/oju.2012.23026

**Iczkowski, K.A.**, Pantazis, C.G. Papillary cystadenofibroma of the epididymis: a case report. *International J Clinical and Experimental Pathology* 2011;4:628-630.

**Iczkowski, K.A.**, Torkko, K.C., Kotnis, G.R., Wilson, R.S., Huang, W., Wheeler, T.M., Abeyta, A.M., Lucia, M.S. Pseudolumen size and perimeter in prostate cancer: correlation with patient outcome. *Prostate Cancer*;2011:693853. Epub 2011 Jul 14.

Zhang, C., Montironi, R., MacLennan, G.T., Lopez-Beltran, A., Li, Y., Tan, P.H., Wang, M., Zhang, S., **Iczkowski, K.A.**, Cheng, L.: Is atypical adenomatous hyperplasia of the prostate a precursor lesion? *The Prostate* 2011;71:1746-1751.

**Iczkowski, K.A.**, Torkko, K.C., Kotnis, G.R., Wilson, R.S., Huang, W., Wheeler, T.M., Abeyta, A.M., La Rosa, F.G., Cook, S., Werahera, P.N., Lucia, M.S. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. *American Journal of Clinical Pathology* 2011;136:98-107.

Khamis, Z.I., **Iczkowski, K.A.**, Sahab, Z.J., Sang Q-X. Protein profiling of isolated leukocytes, myofibroblasts, epithelial, basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues. *J Cancer* 2010;1:70-79.

Alisky, J.M., Tang, Y., Habermehl, G.K., **Iczkowski, K.A.** Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. *International Journal of Clinical and Experimental Medicine* 2010;25:245-7.

Sangoi, A.R., Beck, A.H., Amin, M.B., Cheng, L., Epstein, J.I., Hansel, D.E., **Iczkowski, K.A.**, Lopez-Beltran, A., Oliva, E., Paner, G.P., Reuter, V.E., Ro, J.Y., Shah, R.B., Shen, S.S., Tamboli, P., McKenney, J.K. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. *American Journal of Surgical Pathology* 2010;34:1367-1376.

Qian,J., Bostwick, D.G., **Iczkowski, K.A.**, Lang, K., Betre, K., Wilson, M.J., Le, C., Sinha, A.A. Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy. *Anticancer Research* 2010;30: 719-25.

Yang, K., Tang, Y., Habermehl, G.K., **Iczkowski, K.A.** Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. *BioMed Central Cancer* 2010;10: 16.

Yang, K., Tang Y., **Iczkowski, K.A.** Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression. *American Journal of Translational Research* 2010;2: 88-94.

Vera, P.L., **Iczkowski, K.A.**, Howard, D.J., Jiang, L., Meyer-Siegler, K.L. Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice. *Neurourol Urodyn* 2010;29:1451-7.

Nakamura, K., Kasraeian, A., **Iczkowski, K.A.**, Chang, M., Pendleton, J., Anai, S., Rosser, C.J. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. *BioMed Central Urology* 2009;9:12.

Namiki, K., Goodison, S., Porvasnik, S., Allan, R., **Iczkowski, K.A.**, Urbanek, C., Reyes, L., Sakamoto, N., Rosser, C.J. Persistent exposure to mycoplasma induces malignant transformation of human prostate cells. *PLoS ONE* 2009;Sep 1;4(9):e6872.

Hao, B., Clancy, C.J., Cheng, S., Raman, S.B., **Iczkowski, K.A.**, Nguyen, M.H. Candida albicans RFX2 encodes a DNA binding protein involved in DNA damage responses, morphogenesis, and virulence. *Eukaryotic Cell* 2009;8:627-39.

Yang, K., Handorean, A.M., **Iczkowski, K.A.** MicroRNA 373 and 520c are downregulated in prostate cancer, suppress CD44 translation, and modulate prostate cancer cell invasion. *International J Clinical and Experimental Pathology* 2009;2:361-9.

Handorean, A.M., Yang, K., Flaig, T., Robbins, E. W., **Iczkowski, K.A.** Silibinin suppresses CD44 expression in prostate cancer cells. *American Journal of Translational Research* 1:80-7, 2009.

Badrane, H., Nguyen, M.H., Cheng, S., Kumar, V., Derendorf, H., **Iczkowski, K.A.**, Clancy, C.J. The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. *Microbiology* 2008;154:3296-308.

Robbins, E.W., Travanty, E.A., Yang, K., **Iczkowski, K.A.** MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. *BioMed Central Cancer* 2008;8:260.

Vera, P.L., **Iczkowski, K.A.**, Wang, X., Meyer-Siegler, K.L. Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. *PLoS One* 2008;3(12):e3898.

**Iczkowski, K.A.**, Hossain, D., Torkko, K.C., Qian, J., Lucia, M.S., Wheeler, T.M., Rewcastle, J., Bostwick, D.G. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. *Urology* 2008;71:1166-71.

**Iczkowski, K.A.**, Butler, S.L., Shanks, J.H., Hossain, D., Schall, A., Meiers, I., Zhou, M., Torkko, K.C., Kim, S.J., Maclennan, G.T. Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. *Human Pathology* 2008;39:275-28.

Goodison, S., Nakamura, K., **Iczkowski, K.A.**, Anai, S., Boehlein, S.K., Rosser, C.J. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. *Cytogenet Genome Res* 2007;118:204-13.

Meyer-Siegler, K. L., Vera, P. L., **Iczkowski, K. A.**, Bifulco, C., Lee, A., Gregersen, P. K., Leng, L., Bucala, R. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. *Genes Immun* 2007;8:646-52.

Sahab, Z. J., **Iczkowski, K. A.**, and Sang, Q. X. Anion exchange fractionation of serum proteins versus albumin elimination. *Anal Biochem* 2007;368:24-32.

Ostrov, D.A., Barnes, C.L., Smith, L.E., Binns, S., Brusko, T.M., Brown, A.C., Quint, P.S., Litherland, S. A., Roopenian, D.C., **Iczkowski, K.A.** Characterization of HKE2: an ancient antigen encoded in the major histocompatibility complex. *Tissue Antigens* 2007;69:181-8.

Moore, C.D., **Iczkowski, K.A.**, Algood, C.B., Blue, K.M. Urothelial carcinoma recurrence in ileal orthotopic neobladder: urethrectomy and creation of an ileal conduit. *Urology* 2007;69:184.e11-13.

Cheng, S., Clancy, C.J., Zhang, Z., Hao, B., Wang, W., **Iczkowski, K.A.**, Pfaller, M.A., Nguyen, M.H. Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue. *Cellular Microbiology* 2007;9:492-501. Epub 2006 Sep 20.

**Iczkowski, K.A.**, Montironi, R. Adenoid cystic/basal cell carcinoma of the prostate strongly expresses Her-2/neu. *Journal of Clinical Pathology* 2006;59:1327-30.

Meyer-Siegler, K.L., **Iczkowski, K.A.**, Leng, L., Bucala, R., Vera, P.L. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. *Journal of Immunology* 2006;177:8730-9.

Anai, S., Goodison, S., Shiverick, K., **Iczkowski, K.**, Tanaka, M., Rosser, C.J. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. *Human Gene Therapy* 2006;17:975-84.

Clancy, C.J., Nguyen, M.H., Alandoerffer, R., Cheng, S., **Iczkowski, K.**, Richardson, M., Graybill, J.R. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. *Microbiology* 2006;152:2247-55.

De Marzo, A.M., Platz, E. A., Epstein, J.I., Ali, T., Billis, A., Chan,T.Y., Cheng, L., Datta, M., Egevad, L., Ertoy-Baydar, D., Farre, X., Fine, S.W., **Iczkowski, K.A.**, et al. A working group classification of focal prostate atrophy lesions. *American Journal of Surgical Pathology* 2006;30:1281-91.

(**three shared first authors**) Lee, S., Desai, K.K., **Iczkowski, K.A.**, Newcomer, R.G., Wu, K.J., Zhao, Y.-G., Tan, W.W., Roycik, M.D., and Sang, Q.-X. A. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. *Cell Research* 2006;16:750-8.

**Iczkowski, K.A.**, Omara-Opyene, L.A., Shah, G.V. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. *Anticancer Research* 2006;26 Jul-Aug (4B):2863-72.

Alisky, J.M., Chertkova, E.L., **Iczkowski K.A.** Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. *Medical Hypotheses* 2006;67:1090-4.

Raman, S.B., Nguyen, M.H., Zhang, Z., Cheng, S., Jia, H.Y., Weisner, N., **Iczkowski, K.**, Clancy, C.J. Candida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis. *Molecular Microbiology* 2006;60:697-709.

Meyer-Siegler, K.L., **Iczkowski, K.A.**, Vera, P.L. Macrophage migration inhibitory factor is increased in the urine of patients with urinary tract infection: Macrophage migration inhibitory factor complexes in human urine. *Journal of Urology* 2006;175:1523-8.

Meyer-Siegler, K.L., **Iczkowski, K.A.**, Vera, P.L. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. *BMC Cancer* 2005;5:73. ([http://www.biomedcentral.com/1471-2407/5/73)](http://www.biomedcentral.com/1471-2407/5/73%29).

Schlesinger, C., Bostwick, D.G., **Iczkowski, K.A.** High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: their predictive values for cancer in current practice. *American Journal of Surgical Pathology* 2005;29:1201-7.

Epstein, J.I., Allsbrook, W.C., Amin, M.B., Egevad, L.L., and the ISUP Grading Committee (incl. **Iczkowski, K.A.**). The International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. *American Journal of Surgical Pathology* 2005;29:1228-42.

**Iczkowski, K.A.,** Omara-Opyene, A.L., Kulkarni, T.R., Pansara, M., and Shah, G.V. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. *Anticancer Research* 2005;25:2075-84.

Sabbisetti, V.S., Chirugupati, S., Thomas, S., Vaidya, K.S., Reardon, D., Chiriva-Internati, M., **Iczkowski, K.A.**, Shah, G.V. Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. *International Journal of Cancer* 2005;117:551-60.

Vera, P.L., Iczkowski, K.A., Leng, L., Bucala, R., Meyer-Siegler, K.L. Macrophage migration inhibitory factor is released as a complex with α1-inhibitor-3 in the intraluminal fluid during bladder inflammation in the rat. *Journal of Urology* 2005;174:338-43.

**Iczkowski, K.A.**, Gapin, T.B., Wajsman, Z. Small lymphocytic lymphoma involving an enlarging complex renal cyst. *Archives of Pathology and Laboratory Medicine* 2005;129:111-2.

Cooper, G.R., Staples, E.D., **Iczkowski, K.A.,** Clancy, C.J. Comamonas (Pseudomonas) testosteroni endocarditis. *Cardiovascular Pathology* 2005;14:145-9.

**Iczkowski, K.A.,** Qiu, J., Qian, J., Somerville, M.C., Rittmaster, R.S., Andriole, G.L., Bostwick, D.G. The dual 5α-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. *Urology* 2005;65:76-82.

Jiang, Z., Wu, C.L., Woda, B.A., **Iczkowski, K.A.,** Chu, P.G., Tretiakova, M.S., Young, R.H., Weiss, L.M., Blute, R. D., Brendler, C.B., Krausz, T., Xu, J.C., Rock, K.L., Amin, M.B., Yang, X. J. Alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker. *Histopathology* 2004;45:218-25.

**Iczkowski, K.A**, Omara-Opyene, A.L., Klösel, R. Metafectene is superior to Lipofectamine in the transfection of Gsα prostate cancer cells. *Molecular Biotechnology* 2004;28:97-103.

Omara-Opyene, A.L., Qiu, J., Shah, G., **Iczkowski, K.A.** Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. *Laboratory Investigation* 2004;84:894-907.

(**shared first authors**) Jiang, Z., and **Iczkowski, K.A.**, Woda, B.A., Tretiakova, M., Yang, X.J. P504S immunostaining boosts diagnostic resolution of suspicious foci in prostatic needle biopsies. *American Journal of Clinical Pathology* 2004;121:99-107.

**Iczkowski, K.A.**, Katz, G., Cascione, C.J. Postoperative bladder washing cytology after transurethral resection. Can it predict the recurrence of urothelial carcinoma? *Acta Cytologica* 2004;48:380-4.

**Iczkowski, K.A.**, Huang, W., Mazzucchelli, R., Pantazis, C.G., Stevens, G. R., Montironi, R. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. *Cancer* 2004;100:294-299.

Kelly, B.J., Mrstik, M.E., Ramos-Caro, F.A., **Iczkowski, K.A.** Papular elastolytic giant cell granuloma responding to hydroxychloroquine and quinacrine. *International Journal of Dermatology* 2004;41:1365-1369.

**Iczkowski, K.A.**, Ferguson, K.L., Grier, D.D., Hossain, D., Banerjee, S.S., McNeal, J.E., Bostwick D.G. Adenoid cystic carcinoma of the prostate: clinicopathologic findings in 19 cases. *American Journal of Surgical Pathology* 2003;27:1523-1529.

**Iczkowski, K.A.**, Bai, S., Pantazis, C.G. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. *Anticancer Research* 2003;23:3129-3140.

**Iczkowski, K.A.**, Pantazis, C.G. Overexpression of NSAID-activated gene product in prostate cancer. *International Journal of Surgical Pathology* 2003;11:159-166.

**Iczkowski, K.A.**, Pantazis, C.G., Wollett, F.C. Lobular carcinoma of the breast metastatic to the epidural space: a potential mimic of giant cell bone tumor. *The Breast Journal* 2003;9:44-46.

Bostwick, D.G., de la Roza, G., Dundore, P., Corica, F.A., **Iczkowski, K.A.** Intraepithelial and stromal lymphocytes in the normal human prostate. *The Prostate* 2003;55:187-193.

Katz, G., **Iczkowski, K.A.** Malignant mesothelioma of the tunica vaginalis presenting as hydrocele. *Infections in Urology* 2003;16:22-24.

**Iczkowski, K.A.**, Chen, H.M., Yang, X.J., Beach, R.A. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. *Urology* 2002;60:851-854.

**Iczkowski, K.A.**, Pantazis, C.G. McGregor, D., Wu, Y., Tawfik, O.W. Telomerase subunit hTERT immunoreactivity: a marker for high-grade prostate cancer. *Cancer* 2002;95:2487-2493.

**Iczkowski, K.A.**, Jones, G.L., Casella, G., Seppala, R.J., Jones, G.L., Mishler, B.A., Qian, J., and Bostwick, D.G. Needle core length in sextant biopsy influences prostate cancer detection rate. *Urology* 2002;59:698-703.

**Iczkowski, K.A.**, Zander, D.S., and Clapp, W.C. Malignant mesothelioma of tunica vaginalis testis: a fatal case with liver metastasis. *Journal of Urology* 2002;167:645-646.

Nothnick, W.B., Fan, F., **Iczkowski, K.A.**, Ashwell, R., Thomas, P., and Tawfik, O.W. CD44s expression is reduced in endometriotic lesions compared to eutopic endometrium in women with endometriosis. *International Journal of Gynecologic Pathology* 2001;20:140-146.

**Iczkowski, K.A.**, Shanks, J.H., Gadaleanu, V., Cheng, L., Jones, E.C., Neumann, R., Nascimento, A.G., and Bostwick, D.G. Inflammatory pseudotumor and leiomyosarcoma of urinary bladder: Differential diagnosis and outcome in 37 spindle cell neoplasms. *Modern Pathology* 2001;14:1043-1051.

**Iczkowski, K.A.**, Han A.C., Edelson, M.I., and Rosenblum N.G. Primary vulvar lymphoma which expresses CD44 variant 6 but not cadherins. *Journal of Reproductive Medicine* 2000;45:853-856.

**Iczkowski, K.A.**, and Bostwick, D.G. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious, atypical small acinar proliferation. *Archives of Pathology and Laboratory Medicine* 2000;124:98-107.

Cheville, J.C., Rao, S., **Iczkowski, K.A.**, Lohse, C.M., and Pankratz, V.S. Cytokeratin expression in seminoma of the human testis. *American Journal of Clinical Pathology* 2000;113:583-588.

**Iczkowski, K.A.**, and Bostwick, D.G. Sampling, submission, and report format for multiple prostate biopsies: A 1999 survey. *Urology* 2000;55:568-571.

Khair, A.A., Pacelli, A., **Iczkowski, K.A.**, Cheng. L., Corica. F.A., Larson, T.R., Corica, A., and Bostwick, D.G. Does transurethral microwave thermotherapy have a different effect on prostate cancer than on benign or hyperplastic tissue? *Urology* 1999;54:67-72.

**Iczkowski, K.A.**, Shanks, J., Allsbrook, W.C., Lopez-Beltran, A., Pantazis, C.G., Collins, T.R., Wetherington, R.W., and Bostwick, D.G. Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. *Histopathology* 1999;35:150-156.

**Iczkowski, K.A.**, Cheng, L., Crawford, B.G., and Bostwick, D.G. Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34E12 to discriminate cancer in prostatic epithelium. *Modern Pathology* 1999;12:1-4.

**Iczkowski, K.A.**, Sweat S.D., and Bostwick, D.G. Subepithelial hematoma of the renal pelvis: report of six cases and review of the literature. *Urology* 1999;53:276-279.

Lu, D., Tawfik, O., Pantazis, C., Hobart, W., Chapman, J., and **Iczkowski, K.** Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. *Gynecologic Oncology* 1999;75:84-90.

Corica, F.A., **Iczkowski, K.A.**, Cheng, L., Zincke, H., Blute, M.L., Wendel, A., Sebo, T.J., Neumann, R., and Bostwick, D.G. Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. *Journal of Urology* 1999;161:408-411.

**Iczkowski, K.A.**, Pantazis, C.G., Long, J., Noble, M.J., and Shah, G.V. Expression of salmon calcitonin-like peptide is increased in prostatic adenocarcinoma. *Journal of Urologic Pathology* 1998;8:135-147.

Cheng, L., Sebo, T.J., Bergstralh, E.J., Slezak, J., Neumann, R.M., **Iczkowski, K.A.**, Pisansky, T.M., Zincke, H., and Bostwick, D.G. Predictors of survival in prostate cancer patients treated with salvage radical prostatectomy after irradiation failure. *Cancer* 1998;83:2164-2171.

**Iczkowski, K.A.**, Bostwick, D.G., and Cheville, J.C. Immunohistochemical profile of Sertoli and Leydig cell testicular tumors. *Modern Pathology* 1998;11:774-779.

**Iczkowski, K.A.**, Bassler, T.J., Schwob, V.S., Bassler, I.C., Kunnel, B.S., Orozco, R.E., and Bostwick, D.G. Diagnosis of “suspicious for malignancy” in prostate biopsies: Predictive value for cancer. *Urology* 1998;51:749-758.

**Iczkowski, K.A.**, Shanks, J., and Bostwick, D.G. Loss of CD44 variant expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. *Histopathology* 1998;32:322-327.

Eid, M., Kumar, V., **Iczkowski, K.A.**, and Tindall, D.R. Early growth response gene-1 expression is increased in prostate cancer compared to benign prostate. *Cancer Research* 1998;58:2461-2468.

Bostwick, D.G., **Iczkowski, K.A.**, Amin, M.B., Discigil, G., and Osborne, B. Malignant lymphoma involving the prostate: Report of 62 cases. *Cancer* 1998;83:732-738.

Alisky J., **Iczkowski, K.**, Rapoport, A., and Troitsky, N. Bacteriophages show promise as antimicrobial agents. *Journal of Infection* 1998;36:5-15.

Giacona, M.B., Ruben, G.C., **Iczkowski, K.A.**, Roos, T.B., Porter, D.M., and Sorenson, G.D. Length of soluble DNA strands in blood plasma from patients with pancreatic cancer and healthy controls. *Pancreas* 1998;17:89-97.

**Iczkowski, K.A.**, Kiviat, J., Cheville, J.C., and Bostwick, D.G. Multifocal capillary microangioma of the testis. *Journal of Urologic Pathology* 1997;7:113-119.

Storkel, S., Eble, J.N., Adlakha, K., Amin, M., Blute, M.L., Bostwick, D.G., Darson, M., Delahunt, B., and **Iczkowski, K.A.** Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* 1997;80:987-989.

**Iczkowski, K.A.**, MacLennan, G.T., and Bostwick, D.G. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. *American Journal of Surgical Pathology* 1997;21:1489-1495.

**Iczkowski, K.A.**, Pantazis, C.G., and Collins, J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. *Journal of Urologic Pathology* 1997;6:119-129.

Andorn, A.C., **Iczkowski, K.A.**, Solomon, K., and Saphier, D. Acute non‑pathologic blood pressure changes associated with Buspirone use in psychiatric inpatients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 1995;19:213-221.

**Iczkowski, K.A.**, Schned, A.R., and Rogers, L.A. Synchronous appendiceal goblet cell carcinoid and ileal conventional carcinoid. *Surgical Pathology* 1994;5:263-268.

**Iczkowski, K.A.** and Hertelendy, F. Participation of the cytoskeleton in avian granulosa cell steroidogenesis. *General and Comparative Endocrinology* 1991;82:355-363.

**Iczkowski, K.A.**, Sun, E.L., and Gondos, B. Morphometric study of the prepubertal rabbit testis: Germ cell numbers and seminiferous tubule dimensions. *American Journal of Anatomy* 1991;190:266-272.

Alisky, J.M., **Iczkowski, K.A.**, and Foti, A.A. Chronic fatigue syndrome. *American Family Physician* 1991;44:56-61.

Alisky, J.M. and **Iczkowski, K.A.** Barriers to housing for deinstitutionalized psychiatric patients. *Hospital and Community Psychiatry* 1990;41:93-95.

**(22) Review Articles**

**Iczkowski, K.A.**, van der Kwast, T.A., and Paner, G. The new realization about cribriform prostate cancer. *Advances in Anatomic Pathology* 2018;25(1):31-37.

**Iczkowski, K.A.** Genomic pathology and cancer biomarkers: Prostate cancer. *Critical Reviews in Oncogenesis* 2017;22(5-6):515-525.

Hoang, D., **Iczkowski, K.A.**, Kilari, D., See, W., and Nevalainen, M.T. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. *Oncotarget* 2017;8:3724-3745.

**Iczkowski, K.A**. Intraductal carcinoma of the prostate: emerging support for a unique diagnostic entity. *Pathology Case Reviews* 2014;19:178-183.

**Iczkowski, K.A**. Prostate Pointers and Pitfalls: The 10 most prevalent problems in prostate biopsy interpretation. *Annals of Diagnostic Pathology* 2014;18:301-311.

**Iczkowski, K.A**., and Bostwick, D.G. Atypical small acinar proliferation of the prostate: 16 years’ experience. *Pathology Case Reviews* 2014;19:147-153.

Khamis, Z.I., **Iczkowski, K.A.**, Sang, Q.-X.A. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. *Medicinal Research Reviews* 2012;32:1026-1077.

**Iczkowski, K.A.**, Lucia M.S. Frequency of positive surgical margin at prostatectomy and its effect on patient outcome. *Prostate Cancer* 2011;2011:673021. Epub 2011 Jun 9.

**Iczkowski, K.A.**, Lucia M.S. Current perspectives on Gleason grading of prostate cancer. *Current Urology Reports* 2011;12:216-22.

**Iczkowski, K.A.** Cell adhesion molecule CD44: its functional roles in prostate cancer. *American Journal of Translational Research* 2011;3:1-7.

Shanks, J.H., **Iczkowski, K.A.** Spindle cell lesions of the bladder and urinary tract. *Histopathology* 2009;55:491-504.

**Iczkowski, K.A.** Effect of radiotherapy on non-neoplastic and malignant prostate. *Open Pathol J* 2009;3:64-73.

Shanks, J.H., **Iczkowski, K.A.** Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. *Histopathology* 2009;54:885-900.

**Iczkowski, K.A.** Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high grade PIN, and use of immunostains. *Archives of Pathology and Laboratory Medicine* 2006;130:835-43.

**Iczkowski, K.A.**, Butler, S.L. New immunohistochemical markers in testicular tumors. *Analytical and Quantitative Cytology and Histology* 2006;28:181-7.

Shanks, J.H., **Iczkowski, K.A.** Non-germ cell tumours of the testis. *Current Diagnostic Pathology* 2002;8:83-93.

**Iczkowski, K.A.**, Bostwick, D.G. El effecto de la radioterapia en la histopatologia de la prostata y la determinacion del cancer residual [Histopathology of Radiation Change in the Prostate and Evaluation of Residual Cancer]. *Revisiones en Urología* [Spanish] 2002;3.

**Iczkowski, K.A.** Current issues in prostate needle biopsy interpretation. *LabMedica International* 2001;18 (1):8-11.

**Iczkowski, K.A.**, Bostwick, D.G. Prostate biopsy 1999: Strategies and significance of pathological findings. *Seminars in Urologic Oncology* 1999;17:177-186.

**Iczkowski, K.A.**, Bostwick, D.G. Prostate Biopsy Interpretation: Current Concepts, 1999. *Urologic Clinics of North America* 1999;26:435-452.

Bostwick, D.G., **Iczkowski, K.A.** Microvessel density in prostate cancer: A review. *Seminars in Urologic Oncology* 1998;16:118-123.

Bostwick, D.G. **Iczkowski, K.A.** Minimal criteria for the diagnosis of prostate cancer on needle biopsy (Review). *Annals of Diagnostic Pathology* 1997;1:104-129.

**(21) Editorials, Book Reviews, Letters, and Media**

Case of the Month, January 2018. International Society for Urologic Pathology. Thyroid-like follicular carcinoma with atypical stroma of the kidney

Feature on “Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostate.” Can J Urol 2014;21(Suppl1):70-76. <https://www.urotoday.com/video-lectures/keane-s-corner-from-the-editor/video/469-the-role-of-gdf-15-expression-and-vitamin-d-in-the-prostate.html>

**Iczkowski, K.A.** Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. *European Urology* 2017 Aug;72(2):e36.

**Iczkowski, K.A.** Editorial Comment. Re: Perlis, N., et al. *Journal of Urology* 2017; 197: 75–83. *Journal of Urology* 2017 Jan;197(1):82. Epub 2016 Oct 4.

**Iczkowski, K.A.** Prostate Cancer: Amended Gleason Score Underestimates Adverse Effect of Cribriform Pathology. MedicalResearch.com Interview, posted on June 4, 2016. http://medicalresearch.com/author-interviews/prostate-cancer-amended-gleason-score-underestimates-adverse-effect-of-cribriform/24917/

**Iczkowski, K.A.** Letter about “Self-Referencing Doctors and Appropriate Cancer Care.”*Wall Street Journal*, Nov. 5, 2014 p. A18.

**Iczkowski, K.A.** Beyond the Abstract – The 10 most prevalent problems in prostate biopsy diagnosis. [Commentary.] http://urotoday.com/index.php?Itemid=782&option=com\_content&view=article&catid=1134&id=76442, Nov. 7, 2014.

**Iczkowski, K.A**., and La Rosa, F.G. Gleason 6 cancer is still cancer. Response to "Gleason 6: A serious prostate malignancy--or a toothless lion?" article by Drs. Lepor and Donin. *Oncology* (Williston Park). 2014;28:22, 24, 29.

**Iczkowski, K.A.** Beyond the Abstract - Pseudolumen size and perimeter in prostate cancer- Correlation with patient outcome. www.urotoday.com/prostate-cancer-1014.html, Wed., 28 March 2012.

**Iczkowski, K.A.,** Montironi, R., Cao, D., Magi-Galluzzi, C., Lucia, M.S. Pathology update for urologists. *Prostate Cancer* 2011;2011:183761. Epub 2011 Sep 25.

**Iczkowski, K.A.** Chronic pelvic pain syndrome: a role for aberrant cytokine function. *Journal of Urology* 2010;184:1253-1254.

Lee, W.H., Hung, M.C., **Iczkowski, K.A.**, Languino, L.R., Dubinett, S.M., Wang, D. [The launch of the American Journal of Translational Research.](http://www.ncbi.nlm.nih.gov/pubmed/19966932) *Am J Transl Res.* 2009:1:1.

**Iczkowski, K.A.,** Cheng L. Beyond the Abstract - Inflammatory Myofibroblastic Tumors of the Genitourinary Tract—Single Entity of Continuum? [http://www.urotoday.com](http://www.urotoday.com/), Bladder Cancer Section, Monday, 10 November 2008.

**Iczkowski, K.A.** Prostate Needle Core Sampling: Why Core Length Matters. www.urohealth.org Web Site of HMG Worldwide, Guest Editorials on Prostate Cancer, August 23, 2002.

**Iczkowski, K.A.**, Cheng, L., Qian, J., Shanks, J., Gadaleanu, V., and Bostwick, D.G. ASAP is a valid diagnosis [letter]. *Human Pathology* 1999;30:1403-1404.

**Iczkowski, K.A.**, Bostwick, D.G., and MacLennan, G.T. Atypical small acinar proliferations (in prostate biopsies). Authors’ Response to letter. *American Journal of Surgical Pathology* 1999;23:489-491.

**Iczkowski, K.A.** Re: Editorial comment on clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies [letter]. *Journal of Urol*ogy 1999;161:231.

**Iczkowski, K.A.**, Bostwick, D.G. The pathologist as optimist: Cancer grade deflation in prostatic needle biopsies [Editorial]. *American Journal of Surgical Pathology* 1998;22:1169-70.

**Iczkowski, K.A.**, Bostwick, D.G. Detection of early prostate cancer: serendipitous or systematic? [letter]. *Journal of the American Medical Association* 1998;279:1439.

**Iczkowski, K.A.** Review of *Testicular and Penile Cancer*. Ernstoff, M.S., and Heaney J.A.. Malden, MA: Blackwell Science, 1998. ISBN 0-63204-319-9. In *Journal of Urologic Pathology* 8: April 1998.

**Iczkowski, K.A.** Addicts in short pants (letter against teen smoking). *Newsweek* 1994;(Nov. 28) 124 (22):18.

**Published Illustrations**

Figure 8.4 in Chapter 8, Hayat MA. Microscopy, Immunohistochemistry and Antigen Retrieval Methods. Norwell, MA: Kluwer Academic Publishers, 2002.

Figure in Hayat, MA. Immunohistochemistry of Carcinomas. New York: Springer Verlag, 2002.

*Scientific Meetings Attended*

15th Annual “Current Issues in Surgical Pathology.” Dallas, May 9-11, 1996.

Courses in gastrointestinal, liver, and genitourinary pathology, ASCP/CAP Fall Meeting, San Diego, Oct. 27-Nov. 2, 1996, and Fall Meeting, Philadelphia, Sept. 20-25, 1997.

86th through 102nd Annual Meetings of U.S. and Canadian Society of Pathologists, 1997-2013.

American Assn. Cancer Research: Prostate Cancer conference, Naples, FL, Dec. 5-9, 2001.

 95th Annual Meeting, Orlando, FL, March 27-31, 2004.

**Other Research Experience**

**1998** Corica, F.A., **Iczkowski, K.A.**, Bostwick, D.G. Detection of micrometastases of prostatic adenocarcinoma by immunohistochemical staining versus reverse transcriptase-PCR for prostate specific antigen.

**1993‑5**  **Iczkowski, K.A.**, Joyce, R.M., Levy, N.B., Kritz, A. Enteropathy‑associated T cell lymphoma: potential early diagnosis by PCR from endoscopic biopsies.

**1992‑5** **Iczkowski, K.A.**, Sorenson, G.D. Qualitative and quantitative assessment of plasma DNA in cancer patients. At Dartmouth‑Hitchcock Medical Center, Dept. of Pathology.

**1990‑2** **Iczkowski, K.A**, deMello, D.E., Taylor, W., Heyman, S., Perez, A. Myofibroblastic tumors of the abdomen: role of tumor necrosis factor  in producing constitutional manifestations. At St. Louis University Medical Center, Dept. of Pathology.

**1990‑1** **Iczkowski, K.A.**, Salinas‑Madrigal, L. Association of congenital hepatic fibrosis with autosomal dominant polycystic kidney disease. At St. Louis University Medical Center, Dept. of Pathology.

**1989‑91** Dressler, F.A., **Iczkowski, K.A.**, Gnepp, D.R. Ultrasonic valvuloplasty for aortic stenosis: clinical and pathologic findings in six patients. At St. Louis University Medical Center, Dept. of Pathology.

**Professional Societies**

Life Fellow, College of American Pathologists (CAP), 1995—

Resident Representative from N.H., 1992‑5.

Fellow, American Society for Clinical Pathology (ASCP), 1995—

Fellow, International Society of Urological Pathology, 1997—

Head of Committee to award this society’s **Excellence in Urologic Pathology Research Award** to 3 residents or fellows who present outstanding poster or platform presentations at the USCAP Annual Meeting, 2002-2012

Member, U.S. and Canadian Society of Pathology (USCAP), 1997—

 Abstract reviewer, Genitourinary 2007-2012

 Ambassador 2014-

Member, American Urologic Association, 2012—

Member, Society for Basic Urologic Research, 2004—

Member, Arthur Purdy Stout Society of Surgical Pathologists, 2005—

America’s Registry of Outstanding Professionals, 2006—

Member, Florida Society of Pathologists 2000-07

Member, Florida Medical Association 2000-07

Member, Alachua County Medical Society 2000-07

Member, University of Florida Shands Cancer Center, 2001-07

Member, Milwaukee Area Pathologists, 2013—

**Professional Activities**

**Editorial Board Service**

**2005- 2011** **—** Editorial Board, *Archives of Pathology and Laboratory Medicine*

**2008- present—**Associate Editor-in-Chief, *American Journal of Translational Research*

**2008- 2011 —***Asian Journal of Andrology*

**2008- present—**Editorial Board, *International Journal of Clinical and Experimental Pathology*

**2011- present—**Editorial Board, *BioMed Central Urology*

**2013- present—**Senior Editorial Board, *American Journal of Clinical and Experimental Urology*

**2015- present****—**Editorial Board, *Annals of Diagnostic Pathology*

**2016- present—**Editorial Board, *Clinics in Oncology*

**2016- present—**Editorial Board, *International Journal of Biochemistry and Cell Biology*

**2018- present—**Editorial Board, *Pathology*

**1997–present—**Occasional reviewer for *American Journal of Surgical Pathology, Analytical and Quantitative Cytology and Histology, Archives of Pathology and Laboratory Medicine, Asian Journal of Andrology, Biomed Central Cancer, British Journal of Urology International, Cancer, Cancer Biomarkers, Case Reports in Urology, Current Drug Targets, Expert Review of Anticancer Therapy* (a Medline publication at <http://www.future-drugs.com/loi/era>), *Histology and Histopathology, Human Pathology, International Brazilian Journal of Urology, International Journal of Clinical and Experimental Pathology, International Journal of Cancer, Laboratory Investigation, Medical Practice and Reviews, Modern Pathology (’18), Nature Reviews – Urology, Neoplasia, OncoTargets and Therapy, Journal of Gene Medicine, Journal of Pharmacology and Experimental Therapeutics, Journal of Postgraduate Medicine, Journal of Urology, Nature Clinical Practice Urology, Pathology Research and Practice, Technology in Cancer Research and Treatmen*t, *Saudi Medical Journal*.

**Study Sections**

**2003–2009—**Reviewer on AMA Foundation Seed Grant Research Program Advisory Panel. Category: Neoplastic Diseases. (Meetings held annually. Applicants are medical students and residents.)

**2003—**Reviewed New Researcher Seed Grant Program proposal, “Naturally occurring human monoclonal antibodies recognizing prostate cell-surface antigens” for the VA New-York-New Jersey Healthcare System (VISN 3).

**2006–2008—American Cancer Society** CCE (Cancer Control and Epidemiology) Study Section Reviewer, Research Scholar Grants, twice yearly, ON SITE, Atlanta, GA.

**2009–2011—American Cancer Society** TBE (Tumor Biochemistry and Endocrinology) Study Section Reviewer, Research Scholar Grants, twice yearly, ON SITE, Atlanta, GA.

**2008**—**National Institutes of Health**, NIEHS contracts review of RFP SBIR 103 Phase II, Study Section Reviewer —“Development of an ELISA for Measuring Serum Levels of NAG-1/MIC/GDF-15,” —August, 2008.

**2009—**Health Research Board of Ireland, Strategy and Funding Directorate, grant proposal reviewer of “Determining a miRNA methylation signature and its significance in prostate cancer”

**2010**—United States – Israel Binational Science Foundation (BSF), grant proposal reviewer of “Glycomic and immunologic biomarkers of biochemical recurrence in prostatic fluids” by Lichtenstein and Drake

**2010**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology PBY-1: Grant reviewer, August, ON SITE, Reston, VA

**2011**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology PBY-1 Pre-application reviewer, June

**2012**—**National Institutes of Health**, NCI, “Provocative Questions,” PQ #5 for R01 and R21, February.

**2012**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology PBY-1 Exploration-Hypothesis Development Grant: Pre-application online reviewer, August.

**2012**— **Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology Training Grant TRN-PBY: Grant reviewer, August.

**2013**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology PBY-1 Pre-application reviewer, June

**2013**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology PBY-1: Grant reviewer, ON SITE, Dec. 8- Dec. 10, Baltimore, MD

**2014**—**Department of Defense** Prostate Cancer Research Program (PCRP) Pathobiology Exploration–Hypothesis Development, Clinical and Experimental Therapeutics-1 (EHD-CET-1) Pre-application reviewer, August

**2016**—**Department of Defense** Prostate Cancer Research Program (PCRP) Cell Biology CB-1: Grant reviewer, ON SITE, Nov. 29- Dec. 1, Reston, VA

**2017**—**Department of Defense** Prostate Cancer Research Program (PCRP) Health Disparity Research - 2, HDR-2: Grant reviewer, ON SITE, Nov. 13- Nov. 14, Baltimore, MD

**2018**—**Prostate Cancer UK** Research Innovation Awards Stage 2. Feb. 2018.

**Professional Society Involvement**

**2005—Participant,** Gleasongrading consensus meeting of International Society of Urologic Pathologists (published, *American Journal of Surgical Pathology*) to develop guidelines in prostate cancer grading, San Antonio, TX February 27, 2005.

**2007- 2012—Abstract Review Committee,** U.S. and Canadian Academy of Pathology Annual Meeting

**2009—Participant,** Radical prostatectomy consensus meeting of International Society of Urologic Pathologists to develop guidelines in prostatectomy submission and reporting, Boston, MA March 8, 2009.

**2012—Participant,** Renal tumor consensus meeting of International Society of Urologic Pathologists to develop guidelines Vancouver, Canada, March 17, 2012.

**2015—Participant,** Testicular and Penile consensus meeting of ISUP, Boston, MA

**2015—Member,** Prostate panel,International Society for Urological Pathology. This panel is limited to 24 members and designed for independent review of photomicrographs for standardization of diagnoses in prostatic pathology, ISUP Reference Imagebase.

**2016— Ambassador,** U.S. and Canadian Academy of Pathology

**2006- 2010 and 2016 —Abstract Review Committee,** College of American Pathologists Annual Meeting

**2017-2020** **House of Delegates** (first Alternate), Wisconsin representative for College of American Pathologists

**Community and Other Activity**

**2003–2004 (June–July)—**University of Florida Center for Precollegiate Education, Student Science Training Program: Our laboratory hosted one high school student each summer.

**2004–2006 (Feb.)—**Judge for choosing awardees at the 41st Annual Junior Science, Engineering and Humanities Symposium (high school students), University of Florida

**2005—**ContentReviewer, Rubin, Pathology: Clinicopathologic Foundations of Medicine, 4th Edition. Hagerstown, MD: Lippincott Williams & Wilkins, 2006.

**2006** School Board of Alachua County, FL:

Judge, Lincoln Middle School Science and Engineering Fair, Jan. 10.

**2015—****17 Scientific Advisory Board, 3D Biopsy, LLC.** Helped design new MRI-guided sampling method for the prostate.

**Intramural Committees**

**2016—**Grand Rounds Committee for Pathology Department; **Chairman, 2018**- **present**

**2015—Member, Dissertation Committee** for Physiology Department, Medical College of Wisconsin. For candidate M. Angeles Baker, Oct. 30, 2015.

**2015–2018 —** Research Affairs Committee, Member, and Representative for Pathology Department, Medical College of Wisconsin. Involves intramural grant evaluation and poster evaluation at MCW Research Day annually in September.

**2013–present —** Institutional Review Board, IRB #3, Member, and Representative for Pathology Department (Chair: Ryan Spellecy), Medical College of Wisconsin

**2015–present —**Program Evaluation Committee (PEC) for MCW Surgical Pathology Fellowship

**2013–present —**Member, MCW Cancer Center

**2007**—Committee to select Director of Cytopathology, Univ. Colorado Health Science Center.

**2001**—**2006—**Director, Surgical Pathology resident rotation, Gainesville VAMC. Designed competency-based written guidelines for the rotation and implemented monthly short slide examinations for the residents.

**2004**—**2007—**Member, University of Florida Prostate Cancer Working Group (Research Team)

**2002**—**2007**—Representative for Pathology and Laboratory, Subcommittee for Clinical Investigation, Gainesville, FL, VAMC

**2002**—**2006—**Member, University of Florida Pathology Residency Training Committee

**2003**—**2005—**Reviewer of Abstracts, Resident Research Day, UF Pathology Department

Teaching Assistant in Medical School Pathology: Mayo Clinic (1997), Univ. of Kansas (1995-6), Dartmouth Medical School (1992-5)

Lecturer for Medical Records students’ Pathology course, Univ. of Kansas (Fall, 1996).

Feedback Supervisor of Interviews, Medical Communications Skills Course: St. Louis University, 1989‑90.

**Publicity and Awards**

**2017.** Outstanding Medical Student Teacher, 2016-2017, Medical College of Wisconsin (Curriculum and Evaluation Committee)

**2015.** Outstanding Medical Student Teacher, 2014-2015, Medical College of Wisconsin (Curriculum and Evaluation Committee)

**2004** Listed in Guide to America’s Top Physicians, 2004-2005 Edition, Consumers’ Research Council of America

**2004** Received Society for Basic Urologic Research – 2004 Young Investigator Travel Award for my poster presentation, Savannah, GA, December 9-12.

**2002** Regarding my grant for research on CD44 Expression in Prostate Cancer: Interviewed by Central Florida Public Radio, 9/16/02. Also featured in The Post of the University of Florida Health Science Center, 10/31/02, page 4.

Regarding publication on Telomerase Expression in Prostate Cancer: interviewed and featured by Reuters News Service on their physician web site, [www.reutershealth.com](http://www.reutershealth.com/), 12/17/02.

**1993** Awarded American Society for Investigative Pathology stipend to attend Conference in Molecular Pathology, Bethesda, MD, Oct. 28‑31.

**1992** Distinction in Research Award, St. Louis University School of Medicine

**1992** Herbert B. Taylor Award in Pathology, St. Louis University School of Medicine

**1988** Summer Research Fellowship Grant, in Endocrinology to work on “Cytoskeleton in granulosa cell steroidogenesis” (see publication below). Advisor: David Lagunoff, M.D., Director, Summer Research Program

**1982** Rotary Scholarship for College

**1981-82** National Honor Society

**Invited Presentations**

**2017** Panel Discussant, 96th Annual Meeting of the South Central Section of the AUA, Naples, FL. November 28, 2017.

**2016** Update on Grading prostatic cancer.Seminar, 30 min, taught at Midwestern Surgical Pathology Conference, Milwaukee, WI, Oct. 15, 2016.

**2016** Panel Discussant, 95th Annual Meeting of the South Central Section of the AUA, Colorado Springs, CO. October 1, 2016.

**2015** Urothelial carcinoma: its diagnosis, divergent differentiation, mimics, and markers. Seminar, 30 min, taught at Midwestern Surgical Pathology Conference, Milwaukee, WI, Sept. 11, 2015.

**2014** “MMP-26 Detects Prostate Cancer Regardless of Needle Biopsy Findings.” Talk at Clinical and Translational Science Research Seminar, Medical College of Wisconsin, Nov. 6, 2014.

**2014** Prostate Pathology 2014: Concepts and Controversies. 2-hour course taught in conjunction with Dr. David G. Bostwick, at College of American Pathologists, Chicago, IL, Sept. 8, 2014.

**2014** Decision-Making in Prostate Biopsy Interpretation. Seminar, 30 min, taught at Midwestern Surgical Pathology Conference, Milwaukee, WI, Sept. 14, 2014.

**2013** “Contemporary Morphologic and Molecular Issues in Prostate Pathology.” GoPath Diagnostics’ Webinar Lecture, May 18.

**2012** “Cribriform Pattern of Prostate Cancer.” Department of Pathology, University of Cincinnati, June 1.

**2009** “Cell Adhesion Molecule CD44 in Prostate Cancer.” Division of Endocrinology, Metabolism and Diabetes, Hormone-Related Malignancies Seminar Series, Univ. of Colorado Denver, April 29.

**2008** “Growth and Invasion of Prostate Cancer: Role of CD44 Adhesion Molecule Isoforms, with a Possible Influence by MicroRNAs.” Department of Pathology and Laboratory Medicine Seminar Series, Univ. of Wisconsin, Madison, December 3.

**2008** “Participation of CD44 Splice Isoforms in Growth and Invasion Is Unique in Prostate Cancer.” Department of Pathology Grand Rounds Series, University of Colorado Denver, October 24.

**2005** “Diagnostic and Research Issues in Prostate Pathology.” Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, November 11.

**2005** “Cell Adhesion Molecule CD44: Marker and Target for Gene Therapy in Prostate Cancer. Update on High-Grade PIN and ASAP.” Division of Pathology, City of Hope National Medical Center, Duarte, California, April 21.

**2004** “Functional Role of Cell Adhesion Molecules in Prostate Cancer.” Faculty seminar, Department of Pathology, Immunology, and Laboratory Medicine, U. of Florida, March 24.

**2003** “Functional Role of Cell Adhesion Molecules in Prostate Cancer.” Topics in Cancer and Cell Biology, Department of Anatomy and Cell Biology, U. of Florida, November 7.

**2003** Poster, “Post-operative bladder washing cytology predicts recurrence of urothelial carcinoma” at College of Medicine Research Day, April 11, and VA Research Day, April 21.

**2002** “ New Markers and Issues in Prostate Cancer Diagnosis” Faculty seminar, Department of Pathology, Immunology, and Laboratory Medicine, U. of Florida, April 15.

**1999** Visiting lecturer, “Prostatic Pathology,” Christie Hospital, Manchester, United Kingdom, Oct. 1

**1999** Genitourinary Pathology Panelist and Presenter of "Atypical small acinar proliferation suspicious for but nondiagnostic of malignancy" at U.S. and Canadian Academy of Pathology, San Francisco, CA, March 24.

**1999** Presentation of “Pathology of radiation injury of the prostate”, *ASCP Teleconferences*, Spring 1999 series, April 30

**1997** Poster presentation of “Salmon calcitonin-like peptide: A novel neuroendocrine tumor marker expressed by prostatic adenocarcinoma” at Scientific Sessions of the CAP/ASCP Fall Meeting, Philadelphia, PA, Sept. 20-25

**1997** Presentation of “Controversies in prostate cancer diagnosis” to Pathology Dept., Duke University, Durham, N.C., July 18

**1996** Presentation of “Synchronous appendiceal goblet cell carcinoid and ileal conventional carcinoid” to Kansas Society of Pathologists, Topeka, KS, Nov. 9

**1996** Poster presentation of “Loss of expression of isoforms of the cell adhesion molecule CD44 in prostatic adenocarcinoma and its metastases” at Scientific Sessions of the CAP/ASCP Fall Meeting, San Diego, CA, Sept. 28-Oct. 4

**1996** Presentation of “CD44 isoform expression in benign prostate and prostate cancer” research to Pathology Dept., University of Kansas, Kansas City, KS, May 6

**1995** Presentation of “Insular thyroid carcinoma” to Kansas Society of Pathologists, Wichita, KS, Oct. 28

**1990** Poster presentation of “Participation of the cytoskeleton in avian granulosa cell steroidogenesis” research to Alpha Omega Alpha Student Research Forum, St. Louis Univ., St. Louis, MO. Awarded Third Place.

**1989** Presentation of “Barriers to housing for deinstitutionalized psychiatric patients” to the National Medical Student Forum, Galveston, TX.

**REFERENCES**

Francisco La Rosa, M.D. Associate Professor, Pathology, Univ. of Colorado Denver

 Phone 303-724-3782 Francisco.LaRosa@UCDenver.edu

David G. Bostwick, M.D. Medical Director, Bostwick Laboratories, Glen Allen, VA.

 Phone 800-214-6628 bostwick@bostwicklaboratories.com

Cooley G. Pantazis, M.D. Pathologist, Munroe Regional Medical Center, Ocala, FL.

Phone 352-368-3443 cpantazis@att.net

Liang Cheng, M.D, Professor, Pathology, Indiana University School of Medicine

Phone 317-491-6442 lcheng@iupui.edu

Chester B. Algood, M.D. Assistant Professor, Urology, Shands Hospital at the University of Florida, Gainesville, FL

 Phone 352-392-4504 algoocb@surgery.ufl.edu

Robert L. Low, M.D., Ph.D. Associate Professor and Vice-Chair, Pathology, Univ. of Colorado Denver

 Phone 303-724-4307 Robert.Low@UCDenver.edu

Ivan Damjanov, M.D., Ph.D. Professor and former Chair, Pathology, Univ. of Kansas Medical Center.

Phone 913-588-7045 idamjano@kumc.edu